Why Livestack does not recommend or sell peptides
US law defines a dietary supplement narrowly: a product taken by mouth containing a dietary ingredient — a vitamin, a mineral, an herb or botanical, an amino acid, or certain related substances — intended to supplement the diet. That definition, from the Dietary Supplement Health and Education Act of 1994, is the boundary of what Livestack recommends and monetizes.
Synthetic peptides like BPC-157 fall outside it. They are lab-made compounds studied as investigational substances, not dietary ingredients, so there is no lawful dietary-supplement form to buy. What sells online is unregulated material: no manufacturing oversight, no verified identity or purity, no dosing basis from human trials — because for BPC-157 there are no published human efficacy trials at all.
The consequences follow mechanically from our own rules. Our evidence rubric grades animal-only data D, and grade D never enters a recommendation. Our regulatory screen hard-fails any non-supplement ingredient outside this page. And our offers system is barred from ever attaching a merchant link to one. This is not caution for its own sake — it is what an evidence-first policy produces when the evidence and the legal category are both missing.
None of this predicts what future trials will show. If human evidence arrives and the regulatory picture resolves, our records will change with it. Until then, the honest summary is the one below each entry.
BPC-157
Synthetic peptide — outside the dietary-supplement category. No lawful supplement form exists, and sporting bodies prohibit it.
Everything known about BPC-157 comes from rodent studies, where it is reported to influence tissue-repair signaling in tendon, ligament, and gut models. No published human efficacy trials exist, so none of the rodent findings transfer to a human dose, a human outcome, or a human safety profile.
Material sold online as BPC-157 is unregulated: identity, purity, and sterility are unverified. On our rubric this is grade D evidence in a category we can neither recommend nor monetize.
Records: Narrative review of BPC-157 preclinical literature (rodent tendon, 2018
NMN (nicotinamide mononucleotide)
US regulatory status unresolved — the FDA has taken the position that NMN is excluded from the dietary-supplement definition. Sold widely regardless.
NMN is a precursor in the NAD+ synthesis pathway, and raising NAD+ is the proposed mechanism behind its popularity. The human record so far is small and short: one 25-person trial moved a single measure of muscle insulin sensitivity while most other metabolic endpoints did not change, and a 10-person study measured tolerability only, not efficacy.
That is thin ground for any recommendation, and long-term human data are absent. Combined with the unresolved regulatory status, NMN stays editorial-only on Livestack.
Records: Yoshino M, 2021 · Irie J, 2020
Editorial coverage only — no offers appear on this page, by policy and by architecture.